Floatz logo

Copanlisib

Recurrent Ovarian Endometrioid Adenocarcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
89/ 100

Competitive context

43 Active assets in the Recurrent Ovarian Endometrioid Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Olaparib
University of Colorado, Denver
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine
Mayo Clinic
Phase 2BB

View all 50 →

Same molecule, other indications

Copanlisib is also rated in:

non-Hodgkin lymphomaDormant
B
Indicative ·
61 / 100
View asset →
non-Hodgkin lymphomaDormant
B
Indicative ·
59 / 100
View asset →
Refractory Diffuse Large B-Cell LymphomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →